{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T16:38:20Z","timestamp":1792341500021,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00432-022-04126-7","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T08:02:42Z","timestamp":1656316962000},"page":"941-950","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Anti-PD-1-based immunotherapy plus lenvatinib to treat advanced gallbladder cancer in the elderly: a case series and review of current literature"],"prefix":"10.1007","volume":"149","author":[{"given":"Lantian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kezhong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiawei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"4126_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG (2021) Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol 16:223\u2013249","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"4126_CR2","first-page":"42","volume":"31","author":"MC Bragazzi","year":"2018","unstructured":"Bragazzi MC, Ridola L, Safarikia S, Matteo SD, Costantini D, Nevi L, Cardinale V (2018) New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin. Ann Gastroenterol 31(1):42\u201355","journal-title":"Ann Gastroenterol"},{"key":"4126_CR3","doi-asserted-by":"publisher","first-page":"CMO.S32821","DOI":"10.4137\/CMO.S32821","volume":"10","author":"EU Cidon","year":"2016","unstructured":"Cidon EU (2016) Resectable cholangiocarcinoma: reviewing the role of adjuvant strategies. Clin Med Insights Oncol 10:CMO.S32821","journal-title":"Clin Med Insights Oncol"},{"issue":"1","key":"4126_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3390\/cancers14010233","volume":"14","author":"SL Csoma","year":"2022","unstructured":"Csoma SL, Bedekovics J, Veres G, \u00c1roksz\u00e1ll\u00e1si A, Andr\u00e1s C, M\u00e9hes G, Mok\u00e1nszki A (2022) Circulating cell-free DNA-based comprehensive molecular analysis of biliary tract cancers using next-generation sequencing. Cancers (Basel) 14(1):233","journal-title":"Cancers (Basel)"},{"issue":"3","key":"4126_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ccell.2015.08.004","volume":"28","author":"R Dahan","year":"2015","unstructured":"Dahan R et al (2015) Fc\u03b3Rs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis. Cancer Cell 28(3):285\u2013295","journal-title":"Cancer Cell"},{"issue":"18","key":"4126_CR6","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1056\/NEJM199910283411807","volume":"341","author":"PC de Groen","year":"2019","unstructured":"de Groen PC, Gores GJ, Larusso NF, Gunderson LL, Nagorney DM (2019) Biliary tract cancers. N Engl J Med Overseas Ed 341(18):1368\u20131378","journal-title":"N Engl J Med Overseas Ed"},{"issue":"3","key":"4126_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.12998\/wjcc.v3.i3.231","volume":"3","author":"AN Dwivedi","year":"2015","unstructured":"Dwivedi AN, Jain S, Dixit R (2015) Gall bladder carcinoma: aggressive malignancy with protean loco-regional and distant spread. World J Clin Cases 3(3):231\u2013244","journal-title":"World J Clin Cases"},{"issue":"9","key":"4126_CR8","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(19)30396-1","volume":"20","author":"M Friedlander","year":"2019","unstructured":"Friedlander M, Meniawy T, Markman B, Mileshkin L, Harnett P, Millward M et al (2019) Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a\/b trial. Lancet Oncol 20(9):1306\u20131315","journal-title":"Lancet Oncol"},{"issue":"9","key":"4126_CR9","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1002\/ijc.32041","volume":"144","author":"V Gunda","year":"2019","unstructured":"Gunda V, Gigliotti B, Ashry T et al (2019) Anti-PD-1\/PD-L1therapy augments lenvatinib\u2019s efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer. Int J Cancer 144(9):2266\u20132278","journal-title":"Int J Cancer"},{"issue":"6","key":"4126_CR10","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","volume":"36","author":"JD Hainsworth","year":"2018","unstructured":"Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C et al (2018) Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol 36(6):536\u2013542","journal-title":"J Clin Oncol"},{"issue":"3_suppl","key":"4126_CR11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1200\/JCO.2021.39.3_suppl.320","volume":"39","author":"JJ Harding","year":"2021","unstructured":"Harding JJ, Cleary JM, Quinn DI, Braa I, Abou-Alfa GK (2021) Targeting HER2 ( ERBB2) mutation-positive advanced biliary tract cancers with neratinib: results from the phase II SUMMIT \u2018basket\u2019 trial. J Clin Oncol 39(3_suppl):320","journal-title":"J Clin Oncol"},{"issue":"2","key":"4126_CR12","doi-asserted-by":"publisher","first-page":"594","DOI":"10.4143\/crt.2019.493","volume":"52","author":"J Kang","year":"2020","unstructured":"Kang J, Jeong JH, Hwang HS, Lee SS, Park DH, Oh DW et al (2020) Efficacy and safety of pembrolizumab in patients with refractory advanced biliary tract cancer: tumor proportion score as a potential biomarker for response. Cancer Res Treat 52(2):594\u2013603","journal-title":"Cancer Res Treat"},{"issue":"2","key":"4126_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/19420862.2018.1556465","volume":"11","author":"H Kaplon","year":"2019","unstructured":"Kaplon H, Reichert JM (2019) Antibodies to watch in 2019. Mabs 11(2):219\u2013238","journal-title":"Mabs"},{"issue":"2","key":"4126_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212513","volume":"14","author":"Y Kato","year":"2019","unstructured":"Kato Y, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y, Yamada K et al (2019) Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS ONE 14(2):e0212513","journal-title":"PLoS ONE"},{"issue":"10126","key":"4126_CR15","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126):1163\u20131173","journal-title":"Lancet"},{"issue":"21","key":"4126_CR16","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.3390\/cancers13215257","volume":"13","author":"H Kuipers","year":"2021","unstructured":"Kuipers H, de Bitter TJJ, de Boer MT, van der Post RS, Nijkamp MW, de Reuver PR et al (2021) Gallbladder cancer: current insights in genetic alterations and their possible therapeutic implications. Cancers (Basel) 13(21):5257","journal-title":"Cancers (Basel)"},{"issue":"9","key":"4126_CR17","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.3390\/jcm9092854","volume":"9","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, Kapacee Z, Breeze M, Bell C, Belcher D, Staiger H et al (2020) Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers. J Clin Med 9(9):2854","journal-title":"J Clin Med"},{"issue":"6","key":"4126_CR18","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40265-020-01286-z","volume":"80","author":"A Lee","year":"2020","unstructured":"Lee A, Keam SJ et al (2020) Tislelizumab: first approval. Drugs 80(6):617\u2013624","journal-title":"Drugs"},{"issue":"6","key":"4126_CR19","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/gutjnl-2018-316039","volume":"68","author":"M Li","year":"2019","unstructured":"Li M, Liu F, Zhang F, Zhou W, Jiang X, Yang Y et al (2019) Genomic ERBB2\/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis. Gut 68(6):1024\u20131033","journal-title":"Gut"},{"issue":"21","key":"4126_CR20","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1200\/JCO.2010.28.4075","volume":"28","author":"SJ Lubner","year":"2010","unstructured":"Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC et al (2010) Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol 28(21):3491\u20133497","journal-title":"J Clin Oncol"},{"key":"4126_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.mrrev.2018.08.003","volume":"778","author":"R Mehrotra","year":"2018","unstructured":"Mehrotra R, Tulsyan S, Hussain S, Mittal B, Singh Saluja S, Singh S et al (2018) Genetic landscape of gallbladder cancer: global overview. Mutat Res Rev Mutat Res 778:61\u201371","journal-title":"Mutat Res Rev Mutat Res"},{"issue":"9","key":"4126_CR22","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/ng.3375","volume":"47","author":"H Nakamura","year":"2015","unstructured":"Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M et al (2015) Genomic spectra of biliary tract cancer. Nat Genet 47(9):1003\u20131010","journal-title":"Nat Genet"},{"issue":"8","key":"4126_CR23","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.33013","volume":"147","author":"SA Piha-Paul","year":"2020","unstructured":"Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A et al (2020) Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer 147(8):2190\u20132198","journal-title":"Int J Cancer"},{"key":"4126_CR24","doi-asserted-by":"crossref","unstructured":"Rizzo A, Ricci AD, Tober N, Nigro MC, Mosca M, Palloni A, et al(2020). Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow. Anticancer Res 40(6):3013\u20133030","DOI":"10.21873\/anticanres.14282"},{"issue":"5","key":"4126_CR25","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40265-015-0383-0","volume":"75","author":"LJ Scott","year":"2015","unstructured":"Scott LJ (2015) Lenvatinib: first global approval. Drugs 75(5):553\u2013560","journal-title":"Drugs"},{"issue":"4","key":"4126_CR26","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/hep.30889","volume":"71","author":"K Shigeta","year":"2020","unstructured":"Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A et al (2020) Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology 71(4):1247\u20131261","journal-title":"Hepatology"},{"issue":"8","key":"4126_CR27","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.jmoldx.2020.04.213","volume":"22","author":"RR Singh","year":"2020","unstructured":"Singh RR (2020) Next-generation sequencing in high-sensitive detection of mutations in tumors: challenges, advances, and applications. J Mol Diagn 22(8):994\u20131007","journal-title":"J Mol Diagn"},{"issue":"2","key":"4126_CR28","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41375-019-0545-2","volume":"34","author":"Y Song","year":"2020","unstructured":"Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D et al (2020) Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. Leukemia 34(2):533\u2013542","journal-title":"Leukemia"},{"issue":"6","key":"4126_CR29","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/14737140.2018.1470506","volume":"18","author":"H \u0160tudentov\u00e1","year":"2018","unstructured":"\u0160tudentov\u00e1 H, Vit\u00e1skov\u00e1 D, Melichar B (2018) Lenvatinib for the treatment of kidney cancer. Expert Rev Anticancer Ther 18(6):511\u2013518","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"4126_CR30","doi-asserted-by":"publisher","first-page":"107327481878936","DOI":"10.1177\/1073274818789361","volume":"25","author":"K Suyama","year":"2018","unstructured":"Suyama K, Iwase H (2018) Lenvatinib: a promising molecular targeted agent for multiple cancers. Cancer Control 25(1):1073274818789361","journal-title":"Cancer Control"},{"issue":"8","key":"4126_CR31","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","volume":"4","author":"M Ueno","year":"2019","unstructured":"Ueno M, Ikeda M, Morizane C, Kobayashi S, Ohno I, Kondo S et al (2019) Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol 4(8):611\u2013621","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"4126_CR32","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1186\/s12885-020-07365-4","volume":"20","author":"M Ueno","year":"2020","unstructured":"Ueno M, Ikeda M, Sasaki T, Nagashima F, Mizuno N, Shimizu S et al (2020) Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results. BMC Cancer 20(1):1105","journal-title":"BMC Cancer"},{"issue":"4","key":"4126_CR33","doi-asserted-by":"publisher","first-page":"652","DOI":"10.21037\/jgo.2018.08.18","volume":"10","author":"BA Weinberg","year":"2019","unstructured":"Weinberg BA, Xiu J, Lindberg MR, Shields AF, Hwang JJ, Poorman K et al (2019) Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J Gastrointest Oncol 10(4):652\u2013662","journal-title":"J Gastrointest Oncol"},{"issue":"17","key":"4126_CR34","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1158\/1078-0432.CCR-19-3561","volume":"26","author":"J Xu","year":"2020","unstructured":"Xu J, Bai Y, Xu N, Li E, Wang B, Wang J et al (2020) Tislelizumab plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma and gastric\/gastroesophageal junction adenocarcinoma. Clin Cancer Res 26(17):4542\u20134550","journal-title":"Clin Cancer Res"},{"issue":"10","key":"4126_CR35","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1002\/cam4.2381","volume":"8","author":"YS Zang","year":"2019","unstructured":"Zang YS, Dai C, Xu X, Cai X, Wang G, Wei J et al (2019) Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer. Cancer Med 8(10):4699\u20134708","journal-title":"Cancer Med"},{"issue":"7","key":"4126_CR36","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","volume":"67","author":"T Zhang","year":"2018","unstructured":"Zhang T, Song X, Xu L, Ma J, Zhang Y, Gong W et al (2018) The binding of an anti-PD-1 antibody to Fc\u03b3R\u0399 has a profound impact on its biological functions. Cancer Immunol Immunother 67(7):1079\u20131090","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"4126_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S1470-2045(09)70333-X","volume":"11","author":"AX Zhu","year":"2010","unstructured":"Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H et al (2010) Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 11(1):48\u201354","journal-title":"Lancet Oncol"},{"key":"4126_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-3-319-91442-8_13","volume":"211","author":"S Zsch\u00e4bitz","year":"2018","unstructured":"Zsch\u00e4bitz S, Gr\u00fcllich C (2018) Lenvantinib: a tyrosine kinase inhibitor of VEGFR 1\u20133, FGFR 1\u20134, PDGFR\u03b1, KIT and RET. Recent Results Cancer Res 211:187\u2013198","journal-title":"Recent Results Cancer Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04126-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04126-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04126-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T10:13:19Z","timestamp":1677838399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04126-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["4126"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04126-7","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]},"assertion":[{"value":"4 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}